Skip to main content
. 2021 Jul 21;2021:5520517. doi: 10.1155/2021/5520517

Table 2.

Medical comorbidity data between the two therapy groups.

Medical comorbidities between groups
C K Total P value
(N = 18) (N = 17) (N = 35)
A-fib 0.29651
 N 18 (100.0%) 16 (94.1%) 34 (97.1%)
 Y 0 (0.0%) 1 (5.9%) 1 (2.9%)

Asthma 0.58081
 N 16 (88.9%) 16 (94.1%) 32 (91.4%)
 Y 2 (11.1%) 1 (5.9%) 3 (8.6%)

CAD 0.32411
 N 17 (94.4%) 17 (100.0%) 34 (97.1%)
 Y 1 (5.6%) 0 (0.0%) 1 (2.9%)

Chronic pain 0.51191
 N 17 (94.4%) 15 (88.2%) 32 (91.4%)
 Y 1 (5.6%) 2 (11.8%) 3 (8.6%)

COPD 0.29651
 N 18 (100.0%) 16 (94.1%) 34 (97.1%)
 Y 0 (0.0%) 1 (5.9%) 1 (2.9%)

CPAP 0.58081
 N 8 (44.4%) 6 (35.3%) 14 (40.0%)
 Y 10 (55.6%) 11 (64.7%) 21 (60.0%)

Depression 0.77381
 N 13 (72.2%) 13 (76.5%) 26 (74.3%)
 Y 5 (27.8%) 4 (23.5%) 9 (25.7%)

GERD 0.60051
 N 9 (50.0%) 10 (58.8%) 19 (54.3%)
 Y 9 (50.0%) 7 (41.2%) 16 (45.7%)

HF 0.29651
 N 18 (100.0%) 16 (94.1%) 34 (97.1%)
 Y 0 (0.0%) 1 (5.9%) 1 (2.9%)

HLD 0.35761
 N 10 (55.6%) 12 (70.6%) 22 (62.9%)
 Y 8 (44.4%) 5 (29.4%) 13 (37.1%)

HTN 0.22911
 N 10 (55.6%) 6 (35.3%) 16 (45.7%)
 Y 8 (44.4%) 11 (64.7%) 19 (54.3%)

Morbid obesity
 Y 18 (100.0%) 17 (100.0%) 35 (100.0%)

OA 0.02791
 N 17 (94.4%) 11 (64.7%) 28 (80.0%)
 Y 1 (5.6%) 6 (35.3%) 7 (20.0%)

OSA 0.82591
 N 7 (38.9%) 6 (35.3%) 13 (37.1%)
 Y 11 (61.1%) 11 (64.7%) 22 (62.9%)

PONV 0.96681
 N 17 (94.4%) 16 (94.1%) 33 (94.3%)
 Y 1 (5.6%) 1 (5.9%) 2 (5.7%)

T2DM 0.05291
 N 15 (83.3%) 9 (52.9%) 24 (68.6%)
 Y 3 (16.7%) 8 (47.1%) 11 (31.4%)

1Chi-square test. A-fib = atrial fibrillation, CAD = coronary artery disease, COPD = chronic obstructive pulmonary disease, CPAP = continuous positive airway pressure device use, GERD = gastroesophageal reflux disease, HF = heart failure, HLD = hyperlipidemia, HTN = hypertension, OA = osteoarthritis, OSA = obstructive sleep apnea, PONV = postoperative nausea and vomiting, and T2DM = type 2 diabetes mellitus.